Nurtec Odt Tablet, Orally Disintegrating
Product Images NDC 85766-096

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Nurtec Odt (NDC 85766-096). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F0741274 9808 5644 E053 2995a90a021e

Close-up image of a single white orally disintegrating tablet of NURTEC ODT, containing 75 mg of rimegepant sulfate. The round tablet features two distinct scored indentations on its surface. The product is labeled by Sportpharm LLC for oral administration.*

FDA Label Image

1 (Label)

The packaging label for Nurtec ODT 75 mg orally disintegrating tablets by Sportpharm LLC shows the proprietary name, strength, and dosage form. It includes NDC 85766-096-08, quantity of 8 tablets, and notes distribution by Pfizer Labs. The label also features lot and batch number placeholders, storage instructions, and a barcode.*

FDA Label Image

Image (Nurtec 01)

NURTEC ODT 75 mg orally disintegrating tablets carton containing 8 tablets. The packaging prominently features the product name and strength, with the active ingredient rimegepant sulfate. The labeler is Sportpharm LLC, and the image shows distinct blue and teal diagonal stripes on the left side of the carton.*

FDA Label Image

Chemical Structure (Nurtec 02)

Chemical structure of rimegepant sulfate depicting its molecular arrangement with associated sulfate and water molecules.*

FDA Label Image

Figure 1 (Nurtec 03)

A line graph comparing the percent of subjects achieving pain freedom over time between NURTEC ODT 75 mg and placebo. The x-axis represents time in hours from dose (0 to 2 hours), and the y-axis shows the percent achieving pain freedom (0% to 100%). NURTEC ODT shows a higher percentage achieving pain freedom at each time point compared to placebo.*

FDA Label Image

Figure 2 (Nurtec 04)

A line graph showing the percent achieving MBS (most bothersome symptom) freedom over time, comparing NURTEC ODT 75 mg to placebo. The x-axis represents time in hours from dose, ranging from 0 to 2 hours, and the y-axis shows percent achieving MBS freedom from 0% to 100%. Two lines depict the comparison: a solid line with triangles for NURTEC ODT 75 mg and a dashed line with stars for placebo, indicating NURTEC ODT has a higher percent achieving MBS freedom at each time point.*

FDA Label Image

Figure 3 (Nurtec 05)

A line graph comparing the change from baseline in monthly migraine days between a placebo group and a 75 mg rimegepant group over a three-month period. The graph shows data points with error bars at baseline, month 1, month 2, and month 3, indicating a decrease in migraine days over time for both groups, with the rimegepant group showing a greater reduction.*

FDA Label Image

Figure 4 (Nurtec 06)

A bar graph comparing the percentage of patients achieving various reductions in migraine days per month between placebo and Rimegepant 75 mg groups. The x-axis shows the range of migraine days reduced (>0 to >12), and the y-axis shows the percent of patients. It includes a category for no change or more migraine days per month. Black bars represent Rimegepant 75 mg (N=314), and white bars represent placebo (N=313).*

FDA Label Image

Image (Nurtec 07)

NURTEC ODT 75 mg orally disintegrating tablets packaging containing 1 tablet. The product contains the active ingredient rimegepant sulfate and is labeled for oral administration. The labeler is Sportpharm LLC. The packaging is a small blister pack with a white tablet visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.